OT mobile menu

Search form


Bone and Soft Tissue Cancer Targets

Bone and Soft Tissue Cancer Targets

New evidence is suggesting that extensive immune profiling of sarcomas may unlock likely subtypes susceptible to immunotherapy.

An experimental compound known as G100 may be a potentially viable agent for local control of metastatic soft tissue sarcomas.

Medical researchers at Indiana University Bloomington are reporting that prostate cancer may be much more closely related to Ewing’s sarcoma than previously recognized.

A 37-year old man presents with a bluish lesion in the right arm. After further assessment, a biopsy is performed. What is your diagnosis?

Sarcomas are a heterogeneous and motley collection of cancers, which struggle with an identity crisis on many levels. The trials often lump vastly different subgroups, and are often unable to collect sufficient numbers of any one disease subtype to complete a unique cohort.

Advanced imaging techniques could allow clinicians the ability to determine as early as 9 days into sarcoma treatment whether the therapy will be effective in a given patient, according to a new University of Michigan study.

The concept of individualized or personalized medicine in oncology has evolved from the use of imatinib (Gleevec) to target the breakpoint cluster region-Abelson protein (BCR-ABL) in chronic myelogenous leukemia, to next generation sequencing panels able to provide more complete genetic analysis of a given tumor or malignant cell.

Subscribe to Bone and Soft Tissue Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.